Patients with leukemia and concomitant neutropenia are at high risk of developing invasive fungal infections (IFI) that are associated with high morbidity and mortality. As these patients typically have severe thrombocytopenia, direct diagnostic sampling with invasive procedures is often not possible due to the high peri-interventional risk. Therefore, the presumptive diagnosis of IFI is primarily based on compatible lung findings on computed tomography and serologic detection of fungal cell wall components, which, however, have limited sensitivity and specificity. With the present study, the investigators aim to determine a set of specific volatile biomarkers in leukemia patients with proven or probable IFI using secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS).
Study Type
OBSERVATIONAL
Enrollment
130
Identify volatile biomarkers of IFI by analyzing the breath metabolome of patients with proven or probable IFI according to the criteria outlined by EORTC/MSG and controls.
University Hospital of Zurich
Zurich, Canton of Zurich, Switzerland
RECRUITINGNovel biomarker (m/z value) for IFI by SESI-HRMS
Feature in Mass Spectrometry
Time frame: through study completion, on average after 3 weeks
Specificity and sensitivity of this novel biomarker
Description of Accuracy and Precision of this novel biomarker
Time frame: through study completion, on average after 3 weeks
Anticipation of IFI
Timepoint of first detection in relation to first clinical symptoms of IFI
Time frame: through study completion, on average after 3 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.